OSLO, Norway, June 19, 2018 /PRNewswire/ -- Targovax ASA
("Targovax" or "the Company"; OSE: TRVX), is a clinical stage
company focused on developing and commercializing immune activators
to target hard to treat solid tumors, announces that the European
Patent Office has granted European Patent no 3079715, A Peptide
mixture. The patent protects the composition of Targovax's
mutant-RAS specific neoantigen vaccine TG02, for stimulating the
immune system of cancer patients with RAS mutated tumors.
Targovax's proprietary mutant-RAS neoantigen vaccine platform is
designed to treat patients with tumors harboring RAS mutations.
Mutations in the RAS genes are a driving cause of cancer
development and progression, and is linked to poor prognosis. By
inducing an anti-mutant-RAS specific immune response, the TG
products have the potential to delay disease progression and
increase survival, with a favorable safety profile compared to
chemotherapy and many other treatment options.
TG02 expands the coverage of RAS mutations beyond TG01, and is
targeting all relevant RAS exon 2 oncogenic point mutations which
are found in the vast majority of all RAS mutated cancers.
Currently, TG02 is being tested in an exploratory Phase Ib clinical
trial in patients with locally recurrent RAS-mutated colorectal
cancer in combination with the checkpoint inhibitor KEYTRUDA®
(clinical study CT TG02-01). This study will provide important
clinical data on the safety, immune activation and mechanism of
action of TG02.
Jon Amund Eriksen, inventor of
the TG technology and Co-founder of Targovax, said: "We are
glad to see the European patent for TG02 being granted, further
strengthening Targovax's intellectual property portfolio covering
the very important mutant-RAS trunk neoantigens. RAS is mutated in
20-30% of all cancers, and this 2nd generation product from the TG
platform puts Targovax in a position to address an important unmet
medical need, which could eventually benefit all RAS mutated cancer
patients."
For further information, please contact:
Renate Birkeli
Investor Relations
Phone: +47-922-61-624
Email: renate.birkeli@targovax.com
Media and IR enquires:
Andreas
Tinglum - Corporate Communications (Norway)Phone:
+47-9300-1773
Email: andreas.tinglum@corpcom.no
Simon Conway/Stephanie Cuthbert - FTI Consulting
(International)
Phone: +44-20-3727-1000
Email: Targovax@fticonsulting.com
About Targovax
Activating the patient's immune system to fight
cancer
Targovax (OSE:TRVX) is a clinical stage company focused on
developing and commercializing immune activators to target hard to
treat solid tumors. Immuno-oncology is currently one of the fastest
growing therapeutic fields in medicine.
Targovax's primary product candidate, ONCOS-102, is a
genetically modified oncolytic adenovirus, used as potential
multi-target, neo-antigen therapeutic cancer vaccines. It has been
engineered as an immune activator that selectively targets cancer
cells. In phase I trials it has demonstrated immune activation at
lesional level which was associated with clinical benefit.
ONCOS-102's lead indication is mesothelioma where the virus is
currently being developed in a phase II trial. A second trial, in
advanced melanoma, is expected to produce important proof of
concept data for checkpoint inhibitor refractory patients.
In addition, Targovax has a neo-antigen cancer vaccine under
development targeting tumors that express mutated forms of RAS. Key
proof of concept data for the TG platform from a clinical trial of
TG01 in resected pancreatic cancer patients showed encouraging
overall survival. A next generation product candidate, TG02 is
currently being combined with pembrolizumab in a phase I trial in
colorectal cancer.
Both platforms are protected by an extensive portfolio of IP,
know-how, and have the potential to yield multiple product
candidates.
This information was brought to you by Cision
http://news.cision.com
http://news.cision.com/targovax/r/targovax-granted-eu-patent-for-mutant-ras-neoantigen-platform-2nd-generation-product-tg02,c2551982
View original
content:http://www.prnewswire.com/news-releases/targovax-granted-eu-patent-for-mutant-ras-neoantigen-platform-2nd-generation-product-tg02-300668326.html
SOURCE Targovax